43% Upside Seen For Dova Pharma Following Competitor Product's Poor Results

By: via Benzinga
Analysts at Leerink turned bullish on Dova Pharmaceuticals Inc (NASDAQ: DOVA) after a competitor to the clinical-stage pharmaceutical ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.